Quality & complianceOfficial

Galliprant 100 mg tablets face Danish supply problems into February 2027

🇩🇰 DKMA · Thu 12 Nov 2026

The Danish Medicines Agency lists quality problems as the reason for disrupted supply of Elanco's veterinary Galliprant 100 mg tablets, expected to last until mid-February 2027.

The Danish Medicines Agency (DKMA) has reported current supply problems for Galliprant 100 mg tablets from Elanco Denmark ApS. The notice sits in the agency's veterinary section of supply announcements. It was first published on 8 October 2026 and updated on 12 November 2026.

DKMA gives the active substance as grapiprant and the ATC vet code as QM01AX92. The expected period of disruption runs from the start of October 2026 to mid-February 2027, which is roughly four and a half months.

The agency names quality problems as the cause. The notice gives no further detail on the nature of those problems, the batches affected or any steps the company is taking. It does not mention a safety concern.

DKMA directs questions about the current status to the company rather than the agency. The notice also points readers to its wider page of announcements on medicine supply.

What it means for your team

  • Veterinary supply and availability monitoring teams should note the expected disruption window of October 2026 to mid-February 2027 for the Danish market.
  • The stated cause is quality problems, but the notice gives no details, so teams needing specifics should contact Elanco Denmark ApS directly.
  • The notice does not describe alternatives or remedial measures; the date range may change, as the notice has already been updated once.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →